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Abstract  
 
Myotonic Dystrophy type 1 (DM1) is a dominant neuromuscular disease caused by 
nuclear-retained RNAs containing expanded CUG repeats. These toxic RNAs alter 
activities of RNA splicing factors resulting in alternative splicing misregulation and 
muscular dysfunction. Here we show that the abnormal splicing of DMD exon 78 found 
in dystrophic muscles of DM1 patients is due to the functional loss of MBNL1 and leads 
to the re-expression of an embryonic dystrophin in place of the adult isoform. Forced 
expression of embryonic dystrophin in zebrafish using an exon–skipping approach 
severely impairs mobility and muscle architecture. Moreover, reproducing Dmd exon 78 
missplicing switch in mice induces muscle fiber remodeling and ultrastructural 
abnormalities including ringed fibers, sarcoplasmic masses or Z-band disorganization, 
which are characteristic features of dystrophic DM1 skeletal muscles. Thus, we propose 
that splicing misregulation of DMD exon 78 compromises muscle fiber maintenance and 
contributes to the progressive dystrophic process in DM1. 
 
Introduction  
Myotonic Dystrophy type 1 (DM1), one of the most common neuromuscular disorders in 
adults, is characterized at the skeletal muscle level by progressive weakness, wasting and 
myotonia. DM1 is an autosomal dominant disorder caused by an expanded CTG repeat in the 
3’untranslated region of the DMPK gene1–3, in which expression of pathogenic RNA leads to 
muscular dysfunction. It has been shown that CUG-expanded RNAs (CUGexp-RNA) are 
retained in nuclear aggregates and alter the activities of Muscleblind-like (MBNL) and 
CELF1 RNA binding factors involved in the regulation of alternative splicing during 
development4–10. Notably, functional loss of MBNL proteins due to their sequestration by 
nuclear CUGexp-RNA results in the abnormal embryonic splicing pattern of a subset of pre-
mRNAs in DM1. Among them, missplicing of CLCN1, INR, PKM, CACNA1S and BIN1 pre-
mRNAs have been associated with myotonia, insulin resistance, perturbed glucose 
metabolism and muscle weakness, respectively, all symptoms of DM111–15. Additional 
splicing misregulation events have been described in skeletal muscles of DM1 patients, 
however their consequences on muscle function remain largely unknown. For instance, 
abnormal splicing regulation of DMD exon 78 that leads to the re-expression of an embryonic 
dystrophin isoform and strongly correlates with muscle disease severity in DM1 patients16,17, 
has not been investigated yet. The DMD gene is composed of 79 exons encoding a 427-kDa 
subsarcolemmal dystrophin protein in skeletal muscle. Dystrophin is part of a large 
dystrophin-associated glycoprotein complex (DGC) that stabilizes the membrane of muscle 
fibers and provides a scaffold for force transmission during muscle contraction, as well as 
transduction of extracellular-mediated signals to the muscle cytoskeleton18,19. Moreover, 
muscle degeneration resulting from the expression of truncated dystrophin in Becker 
muscular dystrophy or its loss in Duchenne muscular dystrophy highlights the importance of 
this subsarcolemmal protein for muscle function20,21.  
The switch from embryonic to adult isoforms of dystrophin during muscle development 
involves fine-tuning coordinated alternative splicing transitions of two regions of the gene. 
The first concerns exons 71 to 74 that are all in-frame, and may each be excluded leading to 
shorter dystrophin isoforms in embryonic muscles22–24. This splicing switch is also altered in 
muscle samples of DM1 patients, although it does not perturb dystrophin activity since mice 
deleted for Dmd exons 71 to 74 do not exhibit skeletal muscle abnormalities25. The second 
developmental splicing switch concerns the penultimate exon 78 (of 32bp) that modifies the 
C-terminal (C-ter) tail of dystrophin23,24,25,27. Exclusion of exon 78 from DMD transcripts 
changes the open-reading-frame (ORF) of the last exon 79. The new ORF has a more 
downstream stop codon, producing a dystrophin with a 31 amino acids (aa) tail instead of a 
shorter 13aa tail when exon 78 is included (Supplementary Fig. 1a).  
In this work, we investigate the consequences of DMD exon 78 splicing misregulation on 
muscle function. We show that DMD exon 78 splicing is regulated by MBNL1 during skeletal 
muscle development and modifies dystrophin C-terminus structure leading to a β-sheet C-
terminus in the adult isoform in place of an amphipathic α-helix C-terminus in the embryonic 
isoform. This developmental transition is required for muscle function since forced exclusion 
of dmd exon 78 using an exon–skipping approach in zebrafish severely impairs mobility and 
muscle architecture. Moreover, expression of micro-dystrophin constructs in dystrophin 
deficient mice demonstrates that the presence of the amphipathic α -helix C-terminus is not 
able to improve muscle function in contrast to the β-sheet C-terminus. Finally, we show that 
forced Dmd exon 78 skipping and subsequent embryonic dystrophin re-expression in wild 
type mice leads to muscle fiber remodeling and ultrastructural abnormalities. Similar changes 
have been described in affected muscles of DM1 patients suggesting that abnormal splicing of 
DMD exon 78 could contribute to the progressive dystrophic process in this disease. 
 
 
Results  
DMD exon 78 splicing changes dystrophin C-terminus structure. To assess whether the 
splicing of DMD exon 78 affects the C-terminal structure of dystrophin, we modeled in silico 
the dystrophin C-ter tail primary sequence containing either 13aa (+78 Cter) or 31aa (Δ78 
Cter). As illustrated in figure 1a, the modification of exon 79 ORF due to DMD exon 78 
exclusion results in a complete reorganization of the dystrophin C-terminus molecular 
structure. The predicted fold of the +78 C-ter tail is a β -sheet with 16±1% of hydrophobic 
residues at the surface and a global positive charge (Fig. 1b and Supplementary Fig. 1b, c). 
In contrast the Δ78 C-ter tail forms an amphipathic α-helix, containing 34±3% of hydrophobic 
residues and a global negative charge suggesting different biophysical and functional 
properties. It is noteworthy that the 31aa sequence corresponding to the embryonic dystrophin 
C-ter tail is highly conserved from worm to human supporting a critical function for this 
developmental-regulated domain26.  
 
Splicing switch of DMD exon 78 is regulated by MBNL1. In human, the splicing transition 
of DMD exon 78 occurs between 11 and 18 weeks of development, with its almost complete 
inclusion after 20 weeks of development, corresponding to the formation of the second 
generation of muscle fibers (Fig. 1c). In contrast this splicing switch is impaired after 20 
weeks of development in fetal skeletal muscles of DM1 patients suffering from the severe 
congenital form. A significant 55% exclusion of DMD exon 78 was detected in skeletal 
muscles of congenital DM1 patients carrying large (>1000) CTG expansions (Fig. 1d), as 
previously observed in affected muscles of adult DM1 patients17. To determine whether the 
pathogenic CTG expansion can interfere with the regulation of DMD exon 78 alternative 
splicing, we artificially expressed large expanded CUG repeats in differentiated control 
muscle cells27 . We showed that conditional expression of CUGexp-RNAs that form nuclear 
aggregates leads to the misregulation of DMD exon 78 alternative splicing (Fig. 1e, left 
panel). We then asked whether the MBNL splicing regulators, which are sequestered by 
CUGexp-RNA aggregates could regulate DMD exon 78 splicing. We focused on MBNL1 and 
MBNL2 knowing that MBNL1 is the major MBNL proteins expressed in adult skeletal 
muscle. We performed siRNA-mediated silencing of MBNL1 or both MBNL1 and MBNL2 
in differentiated human muscle cells to mimic the functional loss of MBNL proteins in DM1 
and showed that the silencing of MBNL1 is sufficient to promote an exclusion of DMD exon 
78 (Fig. 1e, right panel). We further investigated the regulation of Dmd exon 78 in Mbnl 
deficient mouse models. Alternative splicing of Dmd exon 78 was not altered in skeletal 
muscle of Mbnl1 deficient mice due to a functional compensatory elevation of Mbnl2 in this 
mouse model28. However, a significant exclusion of Dmd exon 78 in skeletal muscle of 
muscle-specific Mbnl1: Mbnl2 double knockout (Myo-Cre DKO) mice (Fig. 1f) demonstrated 
that MBNL proteins regulate the developmental splicing switch of DMD exon 78. In addition, 
CELF1 that is upregulated in the presence of CUGexp-RNAs was excluded as a regulator 
because its over-expression in mice does not recapitulate Dmd exon 78 exclusion29. 
Altogether, these results indicate that DMD exon 78 missplicing in DM1 skeletal muscle is a 
direct consequence of MBNL1 loss-of-function caused by its sequestration in CUGexp-RNA 
aggregates.  
 
Dmd exon 78 exclusion impairs zebrafish muscle development. To assess whether the 
splicing transition of DMD exon 78 is essential for muscle development, we developed an 
exon-skipping strategy to block the switch from the embryonic to the adult isoform without 
affecting the total amount of dystrophin. We used the zebrafish model because the 31aa C-ter 
tail is conserved in embryonic zebrafish dystrophin and exon 78 inclusion in zebrafish 
orthologous dmd transcripts also occurs during muscle formation, with a complete inclusion 
between 24 and 48 hours post-fertilization (hpf)26,30. To prevent the developmental splicing 
switch of dmd exon 78, antisense morpholinos (AMO) complementary to the 3’ splicing site 
region were injected into one-cell-stage embryos to force the skipping of dmd exon 78, 
thereby maintaining the expression of embryonic dystrophin. A dose-dependent skipping of 
dmd exon 78 was measured in AMO-treated morphants (Fig. 2a) with no effect on total dmd 
mRNA level (p>0.05, n=3 independent pools of injected zebrafish, Student t-test, 
Supplementary Fig. 2a). At the macroscopic level, abnormal splicing of dmd exon 78 in 
zebrafish led to major morphological abnormalities at 24 and 48 hpf. Caudal defects including 
shorter and twisted tails were observed in dmd ∆78 morphants and the severity of the 
phenotype (from moderate at low AMO concentration to severe at high AMO dose) correlated 
with the level of dmd exon 78 skipping (Fig. 2b). Touch-evoked escape tests revealed that 
dmd ∆78 morphants exhibited mobility impairments characterized by a disorganized 
movement pattern in moderately affected morphants to an abnormal “trembling” pattern in 
severely affected morphants (Fig. 2c and Supplementary Video). Regarding skeletal muscle 
organization, the shape of the myoseptum was altered, changing from the classic V-shape in 
wild type embryos to a U-shape in dmd ∆78 morphants (Fig. 2d). Dystrophin immunostaining 
showed that dystrophin Δ78 was correctly localized at the myosepta and confirmed the 
abnormal “U” myoseptum shape in dmd ∆78 morphants (Fig. 2e). Immunostaining of slow 
myosin showed a disorganization of the muscle fibers in dmd ∆78 morphants with a dramatic 
perturbation of muscle fiber alignment and attachment/detachment to the myosepta in the 
severely affected morphants (Fig. 2f). These results are in agreement with the role of 
dystrophin in the formation of a stable muscle attachment to myosepta in zebrafish 
embryos31,32 and demonstrate that the developmental splicing transition of dmd exon 78 
resulting in the removal of the 31aa C-ter tail of dystrophin is required to establish functional 
muscle structure during development. The 31aa C-ter tail renders the embryonic dystrophin 
unable to functionally replace adult dystrophin. 
 
The C-ter tail modulates dystrophin activity in muscle. To test whether the 31aa C-ter tail 
modulates dystrophin activity, we compared the efficiency of two micro-dystrophin (µDys) 
constructs containing either a 13aa tail (µDys-CTL due to the inclusion of exon 78) or a 31aa 
tail (µDys-∆78 due to the lack of exon 78) in restoring muscle function of dystrophin 
deficient (mdx4cv) mice. Adeno-associated virus (AAV2/9) vectors expressing µDys-CTL or 
µDys-Δ78 were injected locally in Tibialis Anterior (TA) muscles of mdx4cv mice. Muscles 
transduced with each construct expressed similar levels of µDys transcripts (p>0.05, n=5, 
Student t-test, Supplementary Fig. 2b-c) as well as comparable numbers of µDys-positive 
fibers (p>0.05, n=5, Student t-test, Supplementary Fig. 2d) and showed expected 
localization of µDys at the sarcolemma (Fig. 3a). Of note, the Dys2 antibody directed against 
a C-ter dystrophin epitope encoded by DMD exons 78-79 confirmed the modification of the 
µDys-Δ78 C-ter tail (Fig. 3a). As described by others for functional µDys constructs33–40, 
mdx4cv muscles injected with µDys-CTL showed a significant reduction in TA muscle weight 
(Fig. 3b) and a significant improvement of the specific maximal force (Fig. 3c) when 
compared to saline-injected contralateral muscles. We then determined the ability of µDys to 
protect skeletal muscle from injury by testing resistance to eccentric contractions. A partial 
but significant improvement of resistance to eccentric contraction was observed in µDys-CTL 
injected muscles compared to saline-injected muscles (p<0.05) (Fig. 3d). In contrast, mdx4cv 
muscles injected with µDys-Δ78 did not exhibit a reduction in TA muscle weight when 
compared with saline-injected contralateral muscles (Fig. 3e). Moreover, expression of µDys-
Δ78 did not improve the specific maximal force (Fig. 3f) and muscle resistance to eccentric 
contractions in mdx4cv mice (Fig. 3g). Because µDys-Δ78 was not able to ameliorate mdx4cv 
muscle function, we evaluated whether the presence of a 31aa C-ter tail in the µDys-Δ78 
compromised the recruitment of the DGC, which is not localized at the membrane in control 
mdx4cv muscle fibers (Fig. 3a). We found that DGC partners such as α-sarcoglycan but also α-
syntrophin and α -dystrobrevin that have binding sites localized near the C-ter domain 
encoded by exon 7841 are correctly localized at the sarcolemma in both µDys-CTL and µDys-
Δ78 injected muscles (Fig. 3a). However, in contrast to µDys-CTL, µDys-Δ78 does not 
improve mdx4cv muscle function indicating that the 31aa C-ter tail perturbs functions of 
dystrophin related to the protection of muscle performance from mechanical stresses induced by 
repeated contractions. 
 
DMD exon 78 is required for muscle fiber maintenance. To further determine whether the 
re-expression of the endogenous embryonic dystrophin isoform having a 31aa C-ter tail 
instead of a 13aa tail is sufficient to affect muscle homeostasis, we artificially skipped Dmd 
exon 78 in skeletal muscles of adult wild-type (wt) mice using an antisense strategy. For this 
purpose, an engineered AAV2/9 vectors expressing optimized U7-snRNAs-antisense 
targeting Dmd exon 78 splicing sites were injected in TA muscles of adult wt mice. RT-PCR 
analysis demonstrated that continuous expression of U7-Dmd-ex78 antisense induces a near 
complete exclusion of Dmd exon 78 (Fig. 4a) without affecting total Dmd mRNA level 
(p>0.05, n=10, paired t-test, Supplementary Fig. 3a). Mass-spectrometry analysis confirmed 
the switch of the dystrophin C-ter tail from 13aa to the expected 31aa in U7-Dmd-ex78 
injected muscles (Supplementary Fig. 3b). As observed with the µDys-∆78 construct, 
dystrophin Δ78 and DGC partners such as α -syntrophin and α -dystrobrevin were correctly 
localized at the sarcolemma (Supplementary Fig. 3c). Six months post-injection, evaluation 
of muscle contractile properties showed that U7-Dmd-ex78 injected muscles have a 
significant reduction of absolute maximal force (p<0.01, n=10, paired t-test; Supplementary 
Fig. 3d) that is related to a decrease in muscle weight (p<0.05 n=10, paired t-test; 
Supplementary Fig. 3e) since specific maximal force remains unchanged (p≥0.05, n=10, 
paired t-test; Supplementary Fig. 3f) when compared to saline injected contralateral muscles. 
Histological analysis of U7-Dmd-ex78 injected muscles revealed fiber size heterogeneity as 
well as structure reminiscent of ringed fibers (Fig. 4b) and a significant reduction of maximal 
muscle cross-section area (CSA) compared to saline injected contralateral muscles (p<0.01 
n=10, paired t-test; Supplementary Fig. 3g). Muscle fiber composition of U7-Dmd-ex78 
injected TA muscles was also altered with a reduced CSA of oxidative type 2a fibers, which 
is associated with an increase in their number and an increased CSA of glycolytic type 2b 
fibers (Fig. 4c). Quantitative RT-PCR analysis of myosin heavy chain mRNA levels 
confirmed the significant increase of the more oxidative type 2a fibers in the U7-Dmd-ex78 
injected muscles (Fig. 4d). No centrally located nuclei were observed in U7-Dmd-ex78 
injected muscles indicating that the associated muscle remodeling was not due to an active 
degeneration/regeneration process as observed in dystrophin-deficient muscles.  
Next, we performed electron microscopy analyses of U7-Dmd-ex78 injected muscles to 
determine whether the modification of the dystrophin C-ter tail impacts the structure of the 
muscle fiber. Six months post-injection, we observed that the 13aa C-ter tail replacement by 
the 31aa C-ter tail in dystrophin leads to distinct ultrastructural abnormalities: i) myofibril 
disorganization showing myofilaments perpendicularly orientated at the periphery of, or 
across, oxidative fibers, which is characteristic of ringed fibers (Fig. 4e, upper panels and 
Supplementary Fig. 4, upper panels), ii) sarcoplasmic masses displaying large areas of 
sarcoplasm at the fiber periphery with a complete absence of myofibrils but numerous 
vacuoles (Fig. 4e, lower panels), iii) focal internal disorganization of the Z-band (Fig. 4e, 
arrows), iv) and finally, dilated sarcoplasmic reticulum in glycolytic fibers (Supplementary 
Fig. 4, lower panels). These findings showed that the 31aa C-ter tail switch mediated by the 
exclusion of exon 78 in Dmd transcripts did not allow dystrophin to maintain correct 
myofibril architecture and ultrastructural organization of muscle fibers. Altogether these 
results indicate that the dystrophin function involved in the maintenance of muscle fiber 
organization during muscle contraction is impaired by the aberrant expression of the 31aa C-
ter α-helix. 
 
 
Discussion 
In this study we demonstrate that the developmental splicing transition of DMD exon 78, 
which is regulated by MBNL1 splicing factor, is essential for skeletal muscle development 
and muscle fiber organization. During muscle development, the sequence and structure of the 
dystrophin C-ter tail is switched from a 31aa residues amphipathic α-helix in the embryonic 
dystrophin isoform to a 13aa residues β -sheet fold in the adult dystrophin isoform. 
Developmental alternative splicing of the penultimate exon 78 is highly conserved throughout 
vertebrates and the 31aa C-ter tail of the embryonic dystrophin isoform is more conserved that 
the adult C-ter tail42 suggesting a critical role for this domain. Indeed, we show that prolonged 
expression of the embryonic dystrophin isoform carrying a 31aa C-ter tail during zebrafish 
development, by forced dmd exon 78 skipping, leads to muscle architecture and mobility 
impairment. Of note, partial skipping of dmd exon 78 in zebrafish is sufficient to produce 
moderate defects. Whether it is the expression of the embryonic dystrophin isoform or the 
absence of the adult isoform that is more likely to cause this phenotype remains to be 
determined. Nevertheless, our results indicate that the 31aa C-ter α-helix impacts dystrophin 
activity. Indeed, the embryonic dystrophin isoform is not able to replace adult dystrophin 
function as shown by micro-dystrophin experiments in dystrophin deficient mice. Because 
aberrant expression of dystrophin C-ter α -helix tail could have different consequences on 
skeletal muscle behavior depending on whether it occurs during developmental stage or post-
natal period, we mimicked Dmd exon 78 splicing misregulation in adult mouse muscles. 
Forced Dmd exon 78 skipping does not compromise membrane integrity or lead to continuous 
cycles of fiber degeneration/regeneration as observed in dystrophin deficient muscles, but 
alters muscle fiber size and composition as well as its organization as shown by the formation 
of ringed fibers, sarcoplasmic masses or Z-band disorganization. This modification of the 
dystrophin C-ter tail does not affect dystrophin localization in the muscle fiber but prevents 
the protection of the sarcomeric apparatus from contraction-induced stress. Altogether, these 
results show that dystrophin function involved in the maintenance of muscle fiber 
organization during muscle contraction is impaired by DMD exon 78 missplicing, in 
particular the aberrant re-expression of the 31aa C-ter α-helix.  
Misregulation of alternative splicing events in DM1 disease is caused by the expression of 
mutant RNA containing expanded CUG repeats that alter the activities of splicing factors. Our 
results show that the functional loss of MBNL1 splicing regulator due to its sequestration in 
nuclear-retained CUGexp-RNAs is responsible for abnormal DMD exon 78 splicing in DM1 
skeletal muscle cells. Among the altered splice events confirmed in skeletal muscles of DM1 
patients, changes of DMD exon 78 splicing strongly correlated with disease severity17. About 
fifty percent of abnormal splicing switch of DMD exon 78 was reported in affected muscle 
biopsies of DM1 patients16,17, however it is unclear whether the percentage of embryonic 
dystrophin re-expression varies among muscle fibers leading to higher level of splicing 
changes in certain fibers. Remarkably, ultrastructure abnormalities such as ringed fibers, 
sarcoplasmic masses or Z-band disorganization observed in muscle fibers of mice expressing 
skipped Dmd exon 78 isoform were also described in skeletal muscle biopsies of DM1 
patients42–44. Although similar muscle fiber abnormalities have also been reported in other 
muscular dystrophies, these ultrastructure changes are commonly found and represent 
characteristic features of DM1 skeletal muscles. Moreover, adult mouse muscles re-
expressing embryonic dystrophin isoform present a typical combination of fiber type changes 
that is also observed in affected skeletal muscle of DM1 patients: increased number of 
oxidative slow twitch fibers with a selective atrophy of these fibers and a hypertrophy of the 
fast-twitch fibers. As abnormal splicing switch of Dmd exon 78 compromises muscle fiber 
maintenance in adult mouse muscle with phenotypic changes that correlate with abnormalities 
described in skeletal muscle biopsies of DM1 patients, we suggest that the inappropriate re-
expression of the embryonic dystrophin isoform carrying a 31aa C-ter tail could contribute to 
the progressive muscle fiber deterioration in DM1. 
In conclusion, our work underlines the critical MBNL1-dependent regulation of DMD exon 
78 splicing for both skeletal muscle development and muscle fiber maintenance. It also 
proposes that the splicing misregulation of DMD exon 78 induced by the expression of 
expanded CTG repeats participates to the progressive dystrophy in DM1. These results are of 
utmost importance for our understanding of the characteristic dystrophic process in Myotonic 
Dystrophy but also in the context of therapeutic development of functional micro-dystrophins 
or truncated dystrophins generated by exon-skipping technologies in Duchenne Muscular 
Dystrophy. 
 Methods 
Molecular modeling. Molecular models were produced by using the de novo PEP-fold 
method45 through the dedicated webserver (http://bioserv.rpbs.univ-paris-
diderot.fr/services/PEP-FOLD/), given no homology sequence were found for the exon 78 
and exon 79 of dystrophin. Submitted primary sequences were SRGRNTPGKPMREDTM 
and SRGHNVGSLFHMADDLGRAMESLVSVMTDEEGAE, respectively, for the +78 C-ter 
(adult ORF) and D78 C-ter (fetal ORF). Secondary structure analyses from the PEP-Fold 
calculations are shown as diagrams indicating a probability (in %) to adopt a coil (green), 
sheet (blue) or helix (red) fold. Electrostatic potentials were computed by using the APBS 
program46  and hydrophobic potentials and molecular surfaces were provided by the Platinum 
webserver (http://model.nmr.ru/platinum/,47). 
 
Zebrafish embryos microinjection and whole-mount immunolabelling. Injections of 
zebrafish were performed in 1–4 cell stage blastulae. Antisense morpholino oligonucleotide 
(AMO; 5’-GTCCGCCTCCTTAGACAGAGGAAAA-3’) was design and manufactured by 
Gene Tools to bind and inhibit specifically dmd exon 78 inclusion. Dose-dependence curves 
of AMO were performed (0.1 to 0.7 mM) and AMOs were injected at a concentration of 0.1 
and 0.3 mM to minimize morpholino-induced developmental delay and toxicity and to yield a 
consistent motor phenotype. After harvesting at 48 hpf developmental stages, zebrafish 
embryos were fixed with PFA 4 % for 2 hours and dehydrated with MetOH 50% during 5 min 
followed by MetOH 100% for 5 min. After permeabilization with 70% EtOH, 20% acetic acid 
in Phosphate buffer saline (PBS) and blocking with 5 % goat-serum, 0.5% triton X-100 
(Sigma-Aldrich), embryos were incubated overnight at 4°C with mouse monoclonal anti-
dystrophin (MANDRA-1, Sigma 1:1000) or mouse monoclonal F59 anti-slow-twitch myosin 
(1:10) in a 5% goat serum, 0.5% triton X-100 solution. Then the embryos were washed in 
PBS containing 0.1% tween-20, incubated overnight at 4°C with cy3-conjugated goat anti-
mouse secondary antibody (Life Technologies; 1:400), washed with PBS containing 0.1% 
tween-20 and mounted in glass slides. 
 
Touch-evoked escape response (TEER). Morphology and behavioral touch responses were 
assessed. Only fish with no obvious developmental deficits were selected to determine the 
TEER. For escape swimming at 48 hpf, embryos were touched lightly at the level of the tail 
with a pincer. Fish that were unable to escape were touched several times (3–4 times) in order 
to ascertain their failure to respond.  
 
Human muscle samples and muscle cells cultures. Skeletal muscle samples were obtained 
from autopsies, in accordance with French legislation on ethical rules. Control and cDM1 
muscle samples were from aborted fetuses showing, respectively, no sign of neuromuscular 
disease (control) and clinical symptoms of congenital DM1 form with large CTGn>1000 
repeats. Muscle cell cultures were derived from primary human satellite cells as previously 
described48. Briefly, myoblasts were grown in DMEM/199 (ratio 4/1) medium (Gibco/Life 
Technologies) supplemented with 20% fetal bovine serum and antibiotics. For differentiation, 
growth medium was removed from confluent cultures and replaced by DMEM medium. All 
cultures were incubated at 37°C in a humid atmosphere containing 5% CO2. For conditional 
expression of CTG repeats, myoblasts were transduced with lentiviral vectors expressing a 
960 CTG Tet-on construct27. For in vitro MBNL silencing experiments, muscle cells were 
transfected with siRNAs (50nM) directed against MBNL1 (5’-
CAGACAGACUUGAGGUAUGdTdT-3’; Eurogentec) and/or MBNL2 (5’-
GAAGAGUAAUUGCCUGCUUUUdTdT-3’; Eurogentec) using LipofectamineR-RNAiMAX 
reagent (Life Technologies) according to the manufacturer’s protocol. 
 
In vivo gene transfer. All mouse procedures were done according to protocol approved by 
the Committee on Animal Resources at the Centre d' Experimentation Fonctionnelle of Pitie-
Salpetriere animal facility and under appropriate biological containment. Adeno-associated 
virus (AAV2/9) vectors were produced using three-plasmid constructs protocol. For 
microdystrophin (µDys) expression, 2-month-old mdx4cv mice were injected into the Tibialis 
anterior (TA) with 50 µl of AAV2/9-µDys vectors containing 2.5x109 viral genomes (vg). 
The murine optimized µDys-CTL construct incorporates deletion of spectrin-like repeat 
domain 4–23 and the µDys ∆78 construct contains an additional deletion of exon 78. For 
optimized U7-snRNA-antisense expression, U7-Dmd ex78 construct was done as previously 
described12 and adult C57BL/6 wt mice were injected into the TA with 40 µl of AAV2/9-U7-
Dmd ex78 containing 1x1011 viral genomes (vg). For each mouse, the left TA muscle was 
injected with AAV and the contralateral muscle was injected with vehicle alone (PBS). 
Animals were sacrificed 2 months after AAV-µDys injection or 6 months after AAV-U7-
Dmd ex78 injection and muscles were collected, snap-frozen in liquid nitrogen-cooled 
isopentane and stored at −80 °C. 
 
RNA extraction and RT-PCR analysis. RNAs were isolated using Tri Reagent (Sigma) 
according to the manufacturer’s protocol. 1 µg of RNA was reverse transcribed using M-
MLV first strand synthesis system according to the manufacturer’s instructions (Invitrogen) in 
a total of 20µl. One µl of cDNA preparation was subsequently used in a semi-quantitative 
PCR analysis according to standard protocol (ReddyMix, Thermo Scientific). PCR 
amplification was carried out for 20-35 cycles within the linear range of amplification for 
each gene. PCR products were resolved on 1% agarose or 5% non-denaturing polyacrylamide 
(for splicing) gels, BET stained and quantified with ImageJ software. The ratios of exon 
inclusion/exclusion were quantified as percentage of inclusion/exclusion relative to total 
intensity of isoform signals. To quantify mRNA expression, Real-time PCR was performed 
using a Lightcycler 480 (Roche). Reactions were performed with SYBR Green kit (Roche) 
according to the manufacturer’s instructions. PCR cycles were a 15 min denaturation step 
followed by 50 cycles with a 94°C denaturation for 15 sec, 58°C annealing for 20 sec, and 
72°C extension for 20 sec. Mouse Rrlp0 mRNA or zebrafish elongation factor alpha (elfa) 
mRNA were used as standard. Data were analysed with the Lightcycler 480 analysis software.  
PCR primer sequences are listed in Supplementary Table S1. 
 
Immunohistochemistry and histology. Hematoxylin and eosin (HE) staining was used to 
examine the overall muscle morphology of 10µm TA muscle sections. For 
immunohistochemistry, muscle cryo-sections were stained using Mouse on Mouse (M.O.M) 
kit (Vector Labs). Primary antibodies were incubated overnight at 4°C followed by 3 washes 
with PBS-0.1% tween, and incubated with goat anti-mouse or goat anti-rabbit secondary 
antibodies (Life Technologies; 1:400) conjugated to Alexa 488, Alexa 555 or Alexa 647. 
Antibodies against dystrophin (Manex1011B, 1:100, mouse monoclonal, gift from Dr. Glenn 
Morris; Dys1 and Dys2, 1:100, mouse monoclonal, Novocastra; MANDRA1, 1:1000, Mouse 
monoclonal, Sigma-Aldrich), α-syntrophin (rabbit polyclonal, 1:200, Abcam), α-dystrobrevin 
(mouse monoclonal, 1:200, BD Biosciences); anti-MHCIIa (SC71, 1:3, mouse monoclonal 
IgG1; Hybridoma DSHB), anti-MHCIIX (6H1, 1:2, mouse monoclonal IgM; Hybridoma 
DHSB), laminin  (1:300, rabbit polyclonal, Chemicon) were used. 
 
Electron microscopy. TA muscles were dissected, cut into small pieces and immediately 
fixed in 2% glutaraldehyde, 2% PFA, 0.1 M phosphate buffer. After abundant washes and 2 
% OsO4 post fixation, samples were dehydrated at 4°C in graded acetone including a 1% 
uranyl acetate in 70° acetone step, and were finally embedded in Epon resin. Thin (70 nm) 
sections were stained with uranyl acetate and lead citrate, observed using a Philips CM120 
electron microscope (Philips Electronics NV) and photographed with a digital SIS Morada 
camera. 
 
In situ force measurement. The isometric contractile properties of TA muscle were studied 
in situ. Mice were anesthetized with pentobarbital (60 mg/kg intraperitoneally). The knee and 
foot were fixed with clamps and pins. The distal tendon of the TA muscle was attached to a 
lever arm of a servomotor system (305B, Dual-Mode Lever). Data were recorded and 
analysed on a microcomputer using PowerLab system (4SP, ADInstruments) and software 
(Chart 4, ADInstruments). The sciatic nerve (proximally crushed) was stimulated by a bipolar 
silver electrode using a supramaximal (10-V) square wave pulse of 0.1 ms duration. All 
contractions were made at an initial length L0 (length at which maximal tension was first 
obtained during tetanic contractions). Absolute maximal isometric tetanic force was measured 
during isometric contractions in response to electrical stimulation (frequency of 25 to 150 Hz, 
train of stimulation of 500ms). Maximal specific isometric force was calculated by dividing 
absolute maximal isometric force by muscle weight. 
Resistance to eccentric (lengthening) contractions of TA muscles was then evaluated by 
measuring the force drop following eccentric contractions. A maximal isomeric contraction of 
the TA muscle was initiated during the first 500 msec. Then, muscle lengthening (1.1 mm, 
10% L0) at a velocity of 0.5 mm/sec (about 0.5 L0/sec) was imposed during the last 200 msec. 
Nine lengthening contractions of the TA muscles were performed, each separated by a 60-sec 
rest period. Maximal isometric force was measured after each eccentric contraction and 
expressed as a percentage of the initial maximal isometric force.  
 
Dystrophin immunoprecipitation and liquid chromatography-MS/MS analysis. TA 
muscles of mice were homogenized in ice-cold lysis buffer (150 mM NaCl, 1% Triton, 0.1% 
SDS, 1% sodium deoxycholate, 150 mM Tris-HCl, pH 8) containing Complete Protease 
Inhibitors and PhosSTOP cocktails (Roche Diagnostics). After 30 min incubation on ice, the 
samples were centrifuged at 14.000g for 15 min to pellet cell debris and protein concentration 
of the supernantant fraction was determinated by Pierce® BCA Protein assay kit (Thermo 
Scientific). Immunprecipitation was performed using 1 mg of protein extract and Pierce® 
Crosslink Immunprecipitation kit (Thermo Scientific) according to the manufacturer’s 
instructions using 25 µg of MANEX 1011B antibody. Proteins were eluted in Laemmli 
Reducing Sample Buffer and separated on SDS-PAGE  
Excised gel slices were washed and proteins were reduced with 10 mM DTT prior to 
alkylation with 55 mM iodoacetamide. After washing and shrinking of the gel pieces with 100 
% acetonitrile, in-gel digestion was performed using trypsin (Sequencing Grade, Promega) 
overnight in 25 mM ammonium bicarbonate at 30°C. The extracted peptides were analyzed 
by nano-LC-MS/MS using an Ultimate 3000 system (Dionex S.A.) coupled to an LTQ-
Orbitrap XL mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Samples were 
loaded on a C18 precolumn (300 µm inner diameter x 5 mm; Dionex) at 20 µl/min in 5% 
acetonitrile, 0.1% TFA. After 3 min of desalting, the precolumn was switched on line with the 
analytical C18 column (75 µm inner diameter x 50 cm; C18 PepMapTM, Dionex) equilibrated 
in solvent A (2% acetonitrile, 0.1% formic acid). Bound peptides were eluted using a two-step 
linear gradient of 157 min (from 0 to 30% (v/v)) and 20 min (from 30 to 50%) of solvent B 
(80 % acetonitrile, 0.085 % formic acid) at a 150 nl/min flow rate and an oven temperature of 
40°C. Data-dependent acquisition was performed on the LTQ-Orbitrap mass spectrometer in 
the positive ion mode. Survey MS scans were acquired in the Orbitrap on the 350-1000 m/z 
range with the resolution set to a value of 100,000. Each scan was recalibrated in real time by 
co-injecting an internal standard from ambient air into the C-trap (‘lock mass option’). The 5 
most intense ions per survey scan were selected for CID fragmentation and the resulting 
fragments were analyzed in the linear trap (LTQ). Target ions already selected for MS/MS 
were dynamically excluded for 30 s. 
Data were acquired using the Xcalibur software (version 2.2) and the resulting spectra where 
then analyzed via the Sequest HT Software created with Proteome Discoverer (version 1.4, 
Thermo Scientific) using the SwissProt Mus musculus database, containing 16620 protein and 
Dystrophin 31aa Cter tail sequence (HNVGSLFHMADDLGRAMESLVSVMTDEEGAE). 
Carbamidomethylation of cysteines, oxidation of methionine, protein N-terminal acetylation 
were set as variable modifications for all Sequest searches. Specificity of trypsin digestion 
was set and two missed cleavage site were allowed. The mass tolerances in MS and MS/MS 
were set to 5 ppm and 0.5 Da, respectively. FDR was set to 1% at the peptide level for all 
searches. 
 
Statistical analysis. For statistical analysis, either Student t-test or one-way ANOVAs were 
used as appropriate using GraphPad Prism software (Version 6, GraphPad Software Inc.).  
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Figure Legends 
Figure 1: DMD exon 78 MBNL-regulated splicing switch changes dystrophin C-ter tail. 
a) PEP-fold analysis of dystrophin +78 and dystrophin ∆78 C-ter structures. b) Surface 
properties of PEP-fold models of dystrophin +78 and dystrophin ∆78 C-ter. Electrostatic 
potentials (upper panel) are shown in blue for electropositive and red for electronegative. 
Hydrophobic and hydrophilic surface potentials (lower panel) are coloured in yellow and 
green, respectively. c) RT-PCR analysis of DMD exon 78 alternative splicing in human 
skeletal muscle samples from control and congenital DM1 (cDM1) fetuses. d) Quantification 
of DMD exon 78 inclusion in skeletal muscle samples from cDM1 compared to control 
fetuses aged between 20 and 37 weeks of development (n=3). e) Upper left panel: RT-PCR 
analysis of endogenous DMD exon 78 inclusion in control differentiated human muscle cells 
with or without expression of conditional 960 CTG repeats. Upper right panel: RT-PCR 
analysis of endogenous DMD exon 78 mRNA in control differentiated human muscle cells 
transfected with siRNAs against MBNL1 or both MBNL1 and MBNL2. Lower panel: 
Quantification of DMD exon 78 inclusion (n=6 from 3 independent experiments). f) RT-PCR 
analysis and quantification of endogenous Dmd mRNA in skeletal muscle samples from wild 
type, Mbnl1-/- Knockout, Mbnl1-/-, Mbnl2+/- Knockout and myo-CRE muscle-specific Mbnl1-/-
, Mbnl2-/- double Knockout (myo-CRE DKO) (n=3). Bars indicates s.e.m and * indicates 
p<0.05; ** indicates p<0.01; *** indicates p<0.001; Student t-test). 
 
Figure 2: Exclusion of dmd exon 78 in zebrafish impairs skeletal muscle development. a) 
RT-PCR of dmd exon 78 performed on total RNA extracts isolated from whole control and 
dmd ∆78 embryos (48 hpf). b) Dose-dependant phenotype of dmd ∆78 embryos: control 
embryos compared to moderate and severe affected dmd ∆78 morphants at 48 hpf (scale bar, 
1mm).  c) Touch-evoked escape test of control embryos compared to moderate and severe 
dmd ∆78 morphants (1 image/0.2sec; scale bar, 1mm).). d) Abnormal myoseptum U-shape in 
dmd ∆78 morphants compared to V-shape in control embryos at 48 hpf (scale bar, 250µm and 
100 µm). e) Dystrophin immunostaining (MANDRA1 antibody) of control embryos 
compared to dmd ∆78 morphants at 48 hpf. f) Slow myosin immunostaining of control 
embryos compared to moderate and severe affected dmd ∆78 morphants at 48 hpf (scale bar, 
50µm and 10µm). 
 
Figure 3: µ-dystrophin with a 31aa C-ter tail fails to ameliorate mdx muscle phenotype. 
a) Dystrophin N-terminal domain (Manex1011B antibody), dystrophin C-terminus domain 
(Dys2 antibody), α -sarcoglycan, α -syntrophin and α -dystrobrevin immunostaining of mdx4cv 
TA muscles injected with saline, AAV2/9-µDys-CTL or AAV2/9-µDys-∆ex78 (scale bar, 
50µm). b & e) TA muscle weight of C57BL/6 control mice (C57, n=8) compared to TA 
muscles of mdx4cv mice (n=8) injected with saline (mdx4cv) or AAV2/9-µDys-CTL (b) or 
AAV2/9-µDys-∆ex78 (e). c & f) Specific maximal force (sP0) of TA muscles of C57BL/6 
control mice (C57, n=8) compared to TA muscles of mdx4cv mice (n=8) injected with saline 
(mdx4cv) or AAV2/9-µDys-CTL (c) or AAV2/9-µDys-∆ex78 (f). d & g) Resistance to 
eccentric contractions. Absolute maximal force (P0) following lengthening contractions of 
TA muscles of C57BL/6 control mice (C57, n=8) compared to TA muscles of mdx4cv mice 
(n=8) injected with saline (mdx4cv) or AAV2/9-µDys-CTL (d) or AAV2/9-µDys-∆ex78 (g). 
Bars indicate s.e.m and “ns” indicates not significant; * indicates p<0.05; ** indicates p<0.01 
compared to mdx4cv condition; one-way Anova with Tukey’s multiple comparisons test. 
 
Figure 4: Dystrophin exon 78 is required for muscle structure maintenance. a) RT-PCR 
analysis and quantification of Dmd exon 78 inclusion in TA muscles (n=10) injected with 
AAV-U7-Dmd-ex78 compared to contralateral TA muscles injected with saline (CTL). b) 
H&E staining in TA muscles injected either with saline (CTL) or AAV-U7-Dmd-ex78 (scale 
bar, 50µm). Inset: higher magnification (2.5x) of a structure reminiscent of ringed fiber shown 
by the arrow. c) Fiber types in TA muscles injected either with saline (CTL) or AAV-U7-
Dmd-ex78 were determined by myosin heavy chain (MyHC) immunostaining: MyHC-IIa in 
red, MyHC-IIx in blue, MyHC-IIb dark, laminin in green. Purple fibers correspond to MyHC-
IIa and MyHC-IIx positive fibers (scale bar, 100µm). d) Quantification of MyHC mRNA 
levels by qRT-PCR (n=10). Bars indicate s.e.m and “ns” indicates not significant; *** 
indicates p<0.001; Student t-test). e) Ultrastructure of representative, longitudinally cut, fibers 
in AAV-U7-Dmd-ex78 injected TA. Upper panel: “ringed fiber”. Sarcomeres are mainly 
longitudinally oriented, but just under the sarcolemma, a band of myofibrils (pseudo-colored 
in green) is transversally oriented as evidenced in the enlarged zone (N, nucleus; M, 
mitochondria; scale bar, 5µm). Lower panel: sarcoplasmic mass. The sarcoplasm beneath its 
sarcolemma appears nearly devoid of myofilaments and the higher magnification shows some 
electrodense remnants of z line material and vacuoles of swollen sarcoplasmic reticulum 
(scale bar, 1µm). In addition focal zones with Z line streaming are also observed in fibers of 
AAV-U7-Dmd-ex78 injected muscles (arrows in right panels). 
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